Ariel Soffer, MD
Cardiovascular Disease · Hollywood, FLNPI 1386682748
Payments from drug & device makers
What this record shows
This record is dominated by other: $9,760 of the $13,506 with a category attached, or 72.3%. Angiodynamics, Inc. accounts for 72.4% of it on its own, with 36 other manufacturers making up the rest. 2025 is the largest year on record at $5,955, more than ten times the $172 reported in 2019.
Across 194 payments — averaging $69.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$10K
- Boston Scientific$474
- Tactile Systems Technology Inc$394
- Amgen$384
- Heartflow, Inc.$310
- Novo Nordisk$268
- plus $2K from 31 others
Across 1 payment — averaging $29,058 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$29K
What the payments were for
- Food & beverage$3,74628%
- Other$9,76072%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 7 | $9,776 |
| Boston Scientific | 14 | $474 |
| Tactile Systems Technology Inc | 44 | $394 |
| Amgen | 22 | $384 |
| Heartflow, Inc. | 3 | $310 |
| Novo Nordisk | 14 | $268 |
| Lilly USA, LLC | 12 | $196 |
| Cashflow Solutions, LLC | 12 | $166 |
| Stryker | 1 | $133 |
| Bard Peripheral Vascular, Inc. | 3 | $123 |
| GSK | 5 | $101 |
| Exact Sciences | 4 | $97 |
| Johnson & Johnson | 5 | $85 |
| Novartis | 4 | $82 |
| Sanofi-aventis U.S. LLC | 4 | $81 |
| Medtronic | 3 | $80 |
| Kowa Pharmaceuticals America, Inc. | 4 | $68 |
| AstraZeneca | 4 | $65 |
| Biocompatibles, Inc. | 2 | $64 |
| Cvrx, Inc. | 3 | $61 |
| Astellas Pharma US Inc | 2 | $53 |
| Esperion Therapeutics, Inc. | 2 | $51 |
| Boehringer Ingelheim | 2 | $48 |
| Pfizer | 2 | $41 |
| Cleerly, Inc. | 2 | $41 |
| Abbott | 2 | $40 |
| AbbVie | 2 | $31 |
| BD | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Philips North America LLC | 1 | $20 |
| Vital Connect, Inc | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $18 |
| Radius Health, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,506 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 25 | $23,712 |
| Repatha SyringeEvolocumab | 12 | $12,017 |
| Repatha SureclickEvolocumab | 13 | $11,968 |
| Ezetimibe | 36 | $943 |
| Atorvastatin Calcium | 72 | $566 |
| Metoprolol Succinate | 39 | $494 |
| Rosuvastatin Calcium | 25 | $459 |
| Losartan Potassium | 15 | $241 |
| Amlodipine Besylate | 19 | $119 |
| Ibuprofen | 11 | $109 |
| Hydrochlorothiazide | 15 | $52 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $41 | $23,71225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Hollywood
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.